MOZART THERAPEUTICS Trademark

Trademark Overview

On Monday, July 25, 2022, a trademark application was filed for MOZART THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the MOZART THERAPEUTICS trademark a serial number of 97518221. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, October 8, 2024. This trademark is owned by Mozart Therapeutics, Inc.. The MOZART THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products and preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, infectious diseases and disorders, cancer, and gastrointestinal diseases and disorders; biological products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; cell therapy products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; therapeutic products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastro...
mozart therapeutics

General Information

Serial Number97518221
Word MarkMOZART THERAPEUTICS
Filing DateMonday, July 25, 2022
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, October 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 13, 2024

Trademark Statements

Goods and ServicesPharmaceutical products and preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, infectious diseases and disorders, cancer, and gastrointestinal diseases and disorders; biological products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; cell therapy products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; therapeutic products, namely, preparations for the prevention and treatment of diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; pharmaceutical products and preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; biological products, namely, preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; cell therapy products, namely preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; therapeutic and medicinal products, namely, preparations for the treatment and prevention diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases and disorders, and cancer; diagnostic biomarker reagents for use in diagnosing, preventing, and treating diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, and cancer; diagnostic agents, preparations, and substances for use in diagnosing, preventing, and treating diseases and disorders, namely, autoimmune diseases and disorders, inflammatory diseases and disorders, infectious diseases and disorders, cancer, and gastrointestinal diseases and disorders
NOT AVAILABLE"THERAPEUTICS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 29, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMozart Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98119
Party NameMozart Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98119

Trademark Events

Event DateEvent Description
Friday, July 29, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 28, 2022NEW APPLICATION ENTERED
Wednesday, May 10, 2023ASSIGNED TO EXAMINER
Thursday, June 1, 2023NON-FINAL ACTION WRITTEN
Thursday, June 1, 2023NON-FINAL ACTION E-MAILED
Thursday, June 1, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, August 29, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 29, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 30, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 10, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 13, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 13, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 8, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Related Keywords

therapeutics mozart disorders diseases namely inflammatory autoimmune products treatment preparations prevention gastrointestinal